皮肤性病诊疗学杂志2024，Vol.31Issue(1)：56-59,4.DOI:10.3969/j.issn.1674-8468.2024.01.010
靶向药在瘢痕疙瘩治疗中的研究进展及应用前景
Research progress on targeted drugs and its applications in the treatment of keloids
摘要
Abstract
Keloid(KD)is a pathological scar caused by excessive proliferation of fibroblasts and excessive deposition of extracellular matrix(ECM)in the skin during wound repair.It is often complicated with pain and pruritus,which can seriously affect the quality of life of patients.Al-though various treatments,such as injections,lasers,and surgeries,are available,the outcome is not satisfactory.Therefore,targeted therapeutic regimens,including a large molecule monoclonal antibody(Dupilumab)and the small molecule targeted drugs(Nintedanib,Sorafenib and Sunitinib),have been deployed to treat keloids.This review summarizes the progress on the treat-ment of keloids with these targeted drugs and their applications in the future.关键词
瘢痕疙瘩/靶向药物/度普利尤单抗/尼达尼布/舒尼替尼/索拉非尼Key words
keloid/targeted drug/Dupliumab/Nintedanib/Sunitinib/Sorafenib引用本文复制引用
高俊智,罗银利,皮龙泉,金哲虎..靶向药在瘢痕疙瘩治疗中的研究进展及应用前景[J].皮肤性病诊疗学杂志,2024,31(1):56-59,4.基金项目
国家自然科学基金(81960561) （81960561）
